Target Name: BLID
NCBI ID: G414899
Other Name(s): breast cancer cell protein 2 | BRCC2 | MGC163235 | Breast cancer cell 2 | BH3-like motif-containing cell death inducer | Breast cancer cell protein 2 | BH3-like motif containing, cell death inducer | MGC163233 | BLID_HUMAN | breast cancer cell 2

Breast Cancer Protein 2: A Potential Drug Target Or Biomarker

Breast cancer is a leading cause of cancer-related deaths in women around the world. The development and progression of breast cancer is a complex process that involves the interplay of multiple factors, including genetic, hormonal, and environmental influences. One of the proteins that has been identified as a potential drug target or biomarker for breast cancer is called breast cancer cell protein 2 (BCP-2).

BCP-2 is a protein that is expressed in the cells of breast cancer tumors. It is a transmembrane protein that is involved in various cellular processes, including cell signaling, migration, and invasion. BCP-2 has been shown to play a role in the development and progression of breast cancer by promoting the growth and survival of cancer cells.

One of the key functions of BCP-2 is its role in cell signaling. BCP-2 is a negative regulator of the PI3K/Akt signaling pathway, which is a critical pathway that is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. In cancer cells, the PI3K/Akt signaling pathway is often disrupted, leading to the uncontrolled growth and survival of cancer cells. By inhibiting the activity of this pathway, BCP-2 has been shown to be an effective drug target for breast cancer.

Another function of BCP-2 is its role in cell migration and invasion. BCP-2 has been shown to play a role in the migration and invasion of cancer cells. It is involved in the production of the protein PDGFR-尾, which is a critical factor in the development of cancer cell migration and invasion. In addition, BCP-2 has been shown to promote the formation of cancer cell-rich microenvironment, which can provide a survival advantage for cancer cells.

In addition to its role in cell signaling and migration, BCP-2 has also been shown to play a role in the regulation of cellular processes such as cell apoptosis, cell cycle progression, and cell growth. In cancer cells, the regulation of these processes is often disrupted, leading to the uncontrolled growth and survival of cancer cells. By promoting the regulation of these processes, BCP-2 has been shown to be an effective drug target for breast cancer.

As a potential drug target or biomarker, BCP-2 has the potential to be a valuable tool for the treatment of breast cancer. By inhibiting the activity of BCP-2, researchers may be able to reduce the growth and survival of cancer cells, leading to a more effective treatment of breast cancer. In addition, BCP-2 may also be a useful biomarker for the diagnosis and prognosis of breast cancer. By measuring the levels of BCP-2 in cancer cells, doctors may be able to determine the effectiveness of different treatments and monitor the progress of breast cancer.

In conclusion, BCP-2 is a protein that has been identified as a potential drug target or biomarker for breast cancer. Its role in cell signaling, migration, and invasion, as well as its role in the regulation of cellular processes such as apoptosis, cycle progression, and growth, make it an attractive target for cancer researchers. As more research is conducted on BCP-2, it is likely that its potential as a drug target or biomarker for breast cancer will be further confirmed.

Protein Name: BH3-like Motif Containing, Cell Death Inducer

Functions: Functions as a proapoptotic molecule through the caspase-dependent mitochondrial pathway of cell death

More Common Targets

BLK | BLM | BLMH | BLNK | BLOC-1 (biogenesis of lysosome-related organelles complex 1) | BLOC1S1 | BLOC1S1-RDH5 | BLOC1S2 | BLOC1S3 | BLOC1S4 | BLOC1S5 | BLOC1S5-TXNDC5 | BLOC1S6 | BLTP1 | BLTP2 | BLTP3A | BLTP3B | BLVRA | BLVRB | BLZF1 | BMAL1 | BMAL2 | BMAL2-AS1 | BMERB1 | BMF | BMI1 | BMP1 | BMP10 | BMP15 | BMP2 | BMP2K | BMP3 | BMP4 | BMP5 | BMP6 | BMP7 | BMP8A | BMP8B | BMPER | BMPR1A | BMPR1B | BMPR1B-DT | BMPR2 | BMS1 | BMS1P1 | BMS1P10 | BMS1P14 | BMS1P15 | BMS1P17 | BMS1P18 | BMS1P2 | BMS1P20 | BMS1P21 | BMS1P22 | BMS1P4 | BMS1P7 | BMS1P8 | BMT2 | BMX | BNC1 | BNC2 | BNC2-AS1 | BNIP1 | BNIP2 | BNIP3 | BNIP3L | BNIP5 | BNIPL | BOC | BOD1 | BOD1L1 | BOD1L2 | BOK | BOK-AS1 | BOLA1 | BOLA2 | BOLA2B | BOLA3 | BOLA3-DT | BOLL | Bombesin receptor | Bone morphogenetic protein (BMP) | Bone Morphogenetic Protein Receptor | Bone Morphogenetic Protein Receptor Type I | BOP1 | BORA | BORCS5 | BORCS6 | BORCS7 | BORCS7-ASMT | BORCS8 | BORCS8-MEF2B | BPESC1 | BPGM | BPHL | BPI | BPIFA1 | BPIFA2 | BPIFA3 | BPIFA4P